Szisztémás szklerózis (szkleroderma): vizsgálatok itt: Kína
65 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- No phaseTaking peopleCAR-T Cells Therapy for Patients With Autoimmune Diseases
- Where
- Hefei
- Életkor
- 18 év and over
- People
- 18
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07052565 - Korai 1. fázisNot yet taking people in KínaClinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 24
- Run by
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT06982534 - 1. fázisTaking peopleA Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 44
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06980597 - 1. fázisNot yet taking people in KínaUCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
- Where
- Changzhou
- Életkor
- 18 év and over
- People
- 18
- Run by
- Changzhou No.2 People's Hospital
See details and how to joinNCT06978738 - Korai 1. fázisNot yet taking people in KínaEarly Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
- Where
- Suzhou
- Életkor
- 18 év and over
- People
- 15
- Run by
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT06970951 - No phaseTaking peopleAn Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 18
- Run by
- The First Affiliated Hospital of University of Science and Technology of China
See details and how to joinNCT06503224 - 2. fázisTaking peopleBCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 50
- Run by
- Peking University People's Hospital
See details and how to joinNCT06794008 - No phaseNot yet taking people in KínaClinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases
- Where
- Hefei
- Életkor
- 18 év to 70 év
- People
- 18
- Run by
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT06871644 - 2. fázisTaking peopleEfficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
- Where
- Hangzhou, Huzhou, Jiaxing, Ningbo, Shanghai, Wenzhou, Yangzhou
- Életkor
- 18 év to 70 év
- People
- 38
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06375005 - 2. fázisTaking peopleA Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
- Where
- Beijing, Chengdu, Jinan, Wuhan
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Changchun GeneScience Pharmaceutical Co., Ltd.
See details and how to joinNCT06189495 - No phaseCsak meghívásosUniversal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 15
- Run by
- Bioray Laboratories
See details and how to joinNCT05859997 - 1. fázisTaking peopleRelmacabtagene Autoleucel for the Treatment of Systemic Sclerosis
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 6
- Run by
- Liangjing Lu
See details and how to joinNCT06414135 - Korai 1. fázisNot yet taking people in KínaThe Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
- Where
- Wenzhou
- Életkor
- 18 év to 65 év
- People
- 9
- Run by
- First Affiliated Hospital of Wenzhou Medical University
See details and how to joinNCT06420154 - No phaseTaking peopleObservational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
- Where
- Beijing, Changsha, Chongqing, Hangzhou, Nanjing, Shenzhen
- Életkor
- Up to 18 év
- People
- 20 000
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT06417502 - 1/2. fázisTaking peopleRY_SW01 Cell Injection Therapy in Systemic Sclerosis
- Where
- Nanjing
- Életkor
- 18 év to 65 év
- People
- 81
- Run by
- Jiangsu Renocell Biotech Company
See details and how to joinNCT06058091